血管内皮抑制素联合培美曲塞及顺铂对晚期肺腺癌患者相关肿瘤因子水平的影响  

Effects of endostatin combined with pemetrexed and cisplatin on the levels of TNF-α,NSE,CEA,CA199,AFP and CYFRA21-1 in patients with advanced lung adenocarcinoma

作　　者：张敏[1] 段爱雄[1] 江启安[1] ZHANG Min;DUAN Ai-xiong;JIANG Qi-an(Department of Oncology ,Anqing Hospitd Affliated to Medicd University Of Anhui, Anqing, Anhui,4600)

机构地区：[1]安徽医科大学附属安庆医院肿瘤内科,安徽安庆246003

出　　处：《海南医学院学报》2017年第20期2846-2849,共4页Journal of Hainan Medical University

基　　金：中华国际医学交流基金(CIMF-F-H001-270)~~

摘　　要：目的:探讨血管内皮抑制素联合培美曲塞及顺铂对晚期肺腺癌患者相关肿瘤因子(TNF-α、NSE、CEA、CA199、AFP和CYFRA21-1)水平的影响。方法:回顾性分析在我院进行诊治的80例晚期肺腺癌患者,分为对照组和观察组。对照组在常规治疗的基础上给予培美曲塞联合顺铂化疗方案,观察组则在对照组治疗的基础上加用血管内皮抑制素进行治疗,检测和比较两组治疗前和治疗后(化疗3个周期)TNF-α、NSE、CEA、CA199、AFP和CYFRA21-1水平的变化。结果:治疗前,两组血清TNF-α、NSE、CEA、CA199、AFP和CYFRA21-1水平之间差异均无统计学意义(P>0.05);治疗后,两组TNF-α、NSE、CEA、CA199、AFP和CYFRA21-1水平与同组治疗前相比,各项指标水平均得到明显改善,差异均具有统计学意义(P<0.05),且观察组各项指标降低幅度大于对照组,差异均存在显著性(P<0.05)。结论:在应用培美曲塞和顺铂治疗晚期肺腺癌患者的基础上加用血管内皮抑制素,可以更加明显地改善患者的血清TNF-α、NSE、CEA、CA199、AFP和CYFRA21-1水平,从一定程度上说明了联合用药更加显著的疗效,值得临床上进一步研究应用。Objective：To investigate the effect of endostatin combined with pemetrexed and cisplatin on the levels of TNF-α,NSE,CEA,CA199,AFP and CYFRA21-1 in patients with advanced lung adenocarcinoma.Methods The retrospective analysis method was used to analyse the 80 patients with advanced adenocarcinoma of the lung in our hospital from January 2013 to January 2017,and patients were divided into two groups：the control group and the observation group.The patients in the control group received pemetrexed combined with cisplatin on the basis of conventional treatment,the observation group was treated with endostatin on the basis of the treatment of the control group,then the changes of TNF-α,NSE,CEA,CA199,AFP and CYFRA21-1 levels in two groups before and after treatment（3 cycles of chemotherapy）were detected and compared.Results Before treatment,there was no significant difference in serum TNF-,NSE,CEA,CA199,AFP and CYFRA21-1 levels between the two groups（P〉0.05）;After treatment,the levels of TNF-α,NSE,CEA,CA199,AFP and CYFRA21-1 in the control group were（5.58±2.43）pg/ml、（17.65±6.97）ng/ml、（6.13±1.14）ng/ml、（62.48±7.86）U/ml、（15.28±4.17）ng/ml、（2.81±0.54）ng/ml,that in the observation group were（4.37±2.15）pg/ml、（11.33±5.24）ng/ml、（4.65±0.88）ng/ml、（51.71±5.23）U/ml、（10.29±3.56）ng/ml、（1.74±0.23）ng/ml,Compared with the same group before treatment,the level of indicators were significantly improved,the difference was statistically significant（P〈0.05）,and The improvement of the indexes in the observation group was obviously better than that in the control group,and the difference was statistically significant（P〈0.05）.Conclusion With the use of pemetrexed and cisplatin in the treatment of advanced lung adenocarcinoma patients,the addition of endostatin could improve the levels of serum TNF-α,NSE,CEA,CA199,AFP and CYFRA21-1 in patients with advanced lung adenocarcinoma,To some extent,it shows that the combined use of drugs is more

关 键 词：晚期肺腺癌 血管内皮抑制素 培美曲塞 顺铂 血清指标 

分 类 号：R734.2[医药卫生—肿瘤]